
IVI Director General Dr. Jerome Kim and Dr. Daniel-Joseph Leung, CEO of Grid, sign an MOU to partner for Epstein-Barr virus vaccine development. Credit: IVI
September 14, 2023, HONG KONG SAR and SEOUL, Republic of Korea – The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Grid Biosciences (Grid), a biotech company developing vaccines and therapeutics aimed at global access and member organization of Hong Kong Science Park, signed a memorandum of understanding to establish a collaborative partnership to pursue joint vaccine research as well as preclinical and clinical development.
IVI and Grid’s collaboration brings together the expertise and resources of both organizations to address the urgent need for a preventative vaccine against the Epstein-Barr virus (EBV). EBV is a common virus that infects the majority of the world’s population. It is the primary cause of infectious mononucleosis and is associated with certain cancers and autoimmune diseases, including multiple sclerosis (MS), nasopharyngeal carcinoma in Asia, and lymphomas in Africa. The development of an effective EBV vaccine has the potential to significantly reduce the global incidence of these diseases.
Grid’s EBV vaccine candidate is based on technology developed by the National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, and is designed to protect against EBV as well as cancers and autoimmune diseases associated with EBV infection. IVI brings to the partnership extensive expertise and experience in the full spectrum of preclinical and clinical development including assay development, in vivo testing, process development, and global clinical trials.
Dr. Jerome Kim, Director General of IVI, said: “We are delighted to partner with Grid Biosciences as Grid shares with IVI a commitment to affordable vaccines for global health, collaboration, and technology transfer, and enabling and developing regional vaccine manufacturing. Putting into place global access strategies from the outset of vaccine development is especially critical for vaccines with high potential impact in low-resource settings, such as a vaccine for Epstein-Barr virus, which has a demonstrated association with Burkitt lymphoma, a cancer endemic in regions of Africa, and nasopharyngeal carcinoma, a cancer found in East Asia. I am highly confident in the complementary capabilities and missions of IVI and Grid Biosciences to make an impact on global health.”
Prof. Thomas Denny, Scientific Advisory Board Chair of Grid, said: “Developing a protective vaccine for acute EBV infection is an important public health aspiration that could also help prevent EBV associated malignancies.”
Dr. Daniel-Joseph Leung, CEO of Grid, added: “Partnering our vaccine development program with IVI’s global vaccine capabilities further our commitment to global access and to ensuring that this new EBV vaccine technology is accessible across geographical borders.”
###
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.
About Grid Biosciences
Grid Biosciences is a biotechnology company focused on the development of innovative vaccines and therapeutics. With a mission to address unmet medical needs, Grid Biosciences collaborates with renowned research institutions and organizations to bring cutting-edge solutions to global health challenges. Grid is a member organization of Hong Kong Science Park and is headquartered there. For more information, please visit https://www.gridbiosciences.com.
CONTACT
IVI:
Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int